NASDAQ:ARAV Aravive (ARAV) Stock Forecast, Price & News $0.13 0.00 (0.00%) (As of 09/28/2023 ET) Add Compare Share Share Today's Range$0.13▼$0.1450-Day Range$0.11▼$1.6552-Week Range$0.11▼$2.46Volume1.79 million shsAverage Volume2.66 million shsMarket Capitalization$9.66 millionP/E RatioN/ADividend YieldN/APrice Target$10.17 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Aravive MarketRank™ ForecastAnalyst RatingHold2.33 Rating ScoreUpside/Downside7,643.1% Upside$10.17 Price TargetShort InterestBearish9.92% of Shares Sold ShortDividend StrengthN/ASustainability-0.52Upright™ Environmental ScoreNews Sentiment0.17Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.61) to ($0.29) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.22 out of 5 stars 3.2 Analyst's Opinion Consensus RatingAravive has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.17, Aravive has a forecasted upside of 7,643.1% from its current price of $0.13.Amount of Analyst CoverageAravive has only been the subject of 4 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted9.92% of the outstanding shares of Aravive have been sold short.Short Interest Ratio / Days to CoverAravive has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aravive has recently increased by 62.95%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAravive does not currently pay a dividend.Dividend GrowthAravive does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAravive has received a 75.87% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Aravive is -0.52. Previous Next 1.8 News and Social Media Coverage News SentimentAravive has a news sentiment score of 0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Aravive this week, compared to 1 article on an average week.Search InterestOnly 5 people have searched for ARAV on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added Aravive to their MarketBeat watchlist in the last 30 days. This is a decrease of -57% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aravive insiders have not sold or bought any company stock.Percentage Held by Insiders60.40% of the stock of Aravive is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 28.48% of the stock of Aravive is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Aravive are expected to grow in the coming year, from ($0.61) to ($0.29) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aravive is -0.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aravive is -0.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAravive has a P/B Ratio of 0.73. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Aravive (NASDAQ:ARAV) StockAravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a license and collaboration agreement with WuXi Biologics (Hong Kong) Limited to identify and develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.Read More ARAV Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ARAV Stock News HeadlinesSeptember 25, 2023 | americanbankingnews.comAravive, Inc. (NASDAQ:ARAV) Receives $10.17 Average PT from AnalystsSeptember 24, 2023 | finance.yahoo.comAravive, Inc. (ARAV) Stock Historical Prices & Data - Yahoo FinanceSeptember 28, 2023 | The Oxford Club (Ad)Better Than Oil Stocks?The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. August 29, 2023 | benzinga.comThinking about buying stock in Limbach Holdings, Aravive, Up Fintech Holding, YS Biopharma, or Big Lots?August 23, 2023 | 247wallst.comCantor Fitzgerald Downgrades AraviveAugust 22, 2023 | msn.comCantor Fitzgerald Downgrades Aravive (ARAV)August 22, 2023 | msn.comCantor cuts Aravive to neutral as biotech struggles to stay in businessAugust 22, 2023 | markets.businessinsider.comAnalyst Downgrades Aravive: Grapples With Trial Setback, Strategic AlternativesSeptember 28, 2023 | Behind the Markets (Ad)How A.I. Could Make Most 21st Century Diseases EXTINCTOn December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...August 4, 2023 | msn.comWilliam Blair Downgrades Aravive (ARAV)August 3, 2023 | msn.comAravive (ARAV) Price Target Decreased by 5.77% to 12.50August 3, 2023 | seekingalpha.comAravive sinks as Phase 3 ovarian cancer trial for lead asset failsAugust 3, 2023 | msn.comAravive (NASDAQ:ARAV) Plummets On Phase 3 Disappointment In Ovarian CancerAugust 3, 2023 | marketwatch.comAravive Shares Hit 52-Week Low After Trial Misses Primary EndpointAugust 3, 2023 | markets.businessinsider.comH.C. Wainwright downgrades Aravive (ARAV) to a HoldAugust 3, 2023 | msn.comWhy Is Aravive Stock Sinking Today?August 3, 2023 | finance.yahoo.comAravive Announces Top-Line Results from Phase 3 AXLerate-OC Study of Batiraxcept in Platinum-Resistant Ovarian CancerAugust 3, 2023 | investorplace.comWhy Is Aravive (ARAV) Stock Down 58% Today?July 28, 2023 | finance.yahoo.comAravive to Present Updated Clinical Data from Batiraxcept Trials in Renal and Pancreatic Cancer at ESMO Congress 2023July 19, 2023 | finance.yahoo.comAravive, Inc.'s (NASDAQ:ARAV) largest shareholders are private equity firms with 50% ownership, individual investors own 22%July 14, 2023 | finance.yahoo.comAravive to Participate in William Blair’s Innovator Series: Transitioning Biotech Breakthroughs to Commercial Success Being Held July 18, 2023July 3, 2023 | benzinga.comCantor Fitzgerald Reiterates Overweight on Aravive, Maintains $18 Price TargetJuly 3, 2023 | markets.businessinsider.comThe Latest Analyst Ratings for AraviveJuly 3, 2023 | benzinga.comPediatric Growth Hormone Deficiency Market expected to rise | Companies – Ascendis Pharma, OPKO Health, Aravive, expected to drive marketJune 20, 2023 | finance.yahoo.comARAV Jul 2023 7.500 callJune 13, 2023 | finance.yahoo.comAravive Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)June 5, 2023 | finance.yahoo.comAravive To Participate in the Jefferies Global Healthcare ConferenceSee More Headlines Receive ARAV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aravive and its competitors with MarketBeat's FREE daily newsletter. Email Address ARAV Company Calendar Last Earnings8/21/2023Today9/28/2023Next Earnings (Estimated)11/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ARAV CUSIPN/A CIK1513818 Webwww.aravive.com Phone(936) 355-1910FaxN/AEmployees23Year FoundedN/APrice Target and Rating Average Stock Price Forecast$10.17 High Stock Price Forecast$18.00 Low Stock Price Forecast$2.00 Forecasted Upside/Downside+7,649.0%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-76,320,000.00 Net Margins-834.54% Pretax Margin-834.54% Return on Equity-1,865.78% Return on Assets-100.55% Debt Debt-to-Equity RatioN/A Current Ratio1.55 Quick Ratio1.55 Sales & Book Value Annual Sales$9.14 million Price / Sales1.06 Cash FlowN/A Price / Cash FlowN/A Book Value$0.18 per share Price / Book0.73Miscellaneous Outstanding Shares73,560,000Free Float29,131,000Market Cap$9.65 million OptionableOptionable Beta2.41 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. Fredric N. Eshelman Pharm.D. (Age 74)Exec. Chairman Comp: $95kDr. Gail F. McIntyre CH (ASCP) (Age 60)DABT, Ph.D., Pres, CEO & Director Comp: $803.99kMr. Rudy C. Howard B.A. (Age 65)CPA, CPA, Chief Financial Officer Comp: $500.26kDr. Jeffrey L. Cleland Ph.D. (Age 58)Co-Founder Dr. Joshua Silverman Ph.D.Co-FounderMr. Marek Ciszewski J.D.VP of Investor RelationsDr. Randy L. AndersonSr. VP of Data SciencesDr. Robert B. Geller M.D. (Age 69)Chief Medical Officer Ms. Carolina PetriniChief Commercial OfficerMore ExecutivesKey CompetitorsLucy Scientific DiscoveryNASDAQ:LSDIAlterity TherapeuticsNASDAQ:ATHEAtrecaNASDAQ:BCELChemomab TherapeuticsNASDAQ:CMMBGT BiopharmaNASDAQ:GTBPView All CompetitorsInstitutional OwnershipAffinity Asset Advisors LLCBought 861,200 shares on 8/21/2023Ownership: 0.000%BlackRock Inc.Bought 112,269 shares on 8/11/2023Ownership: 0.536%Geode Capital Management LLCBought 88,841 shares on 8/11/2023Ownership: 0.508%Renaissance Technologies LLCBought 61,532 shares on 8/11/2023Ownership: 0.358%Assenagon Asset Management S.A.Sold 180,113 shares on 7/25/2023Ownership: 0.034%View All Institutional Transactions ARAV Stock - Frequently Asked Questions Should I buy or sell Aravive stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aravive in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" ARAV shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ARAV, but not buy additional shares or sell existing shares. View ARAV analyst ratings or view top-rated stocks. What is Aravive's stock price forecast for 2023? 6 analysts have issued 12-month target prices for Aravive's shares. Their ARAV share price forecasts range from $2.00 to $18.00. On average, they expect the company's share price to reach $10.17 in the next twelve months. This suggests a possible upside of 7,649.0% from the stock's current price. View analysts price targets for ARAV or view top-rated stocks among Wall Street analysts. How have ARAV shares performed in 2023? Aravive's stock was trading at $1.32 at the start of the year. Since then, ARAV shares have decreased by 90.1% and is now trading at $0.1312. View the best growth stocks for 2023 here. Are investors shorting Aravive? Aravive saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 7,300,000 shares, an increase of 62.9% from the August 31st total of 4,480,000 shares. Based on an average trading volume of 6,950,000 shares, the days-to-cover ratio is currently 1.1 days. View Aravive's Short Interest. When is Aravive's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023. View our ARAV earnings forecast. How were Aravive's earnings last quarter? Aravive, Inc. (NASDAQ:ARAV) announced its earnings results on Monday, August, 21st. The company reported ($0.12) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.18. The company had revenue of $1.27 million for the quarter, compared to analyst estimates of $1 million. Aravive had a negative trailing twelve-month return on equity of 1,865.78% and a negative net margin of 834.54%. What other stocks do shareholders of Aravive own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aravive investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Applied Genetic Technologies (AGTC), Flexion Therapeutics (FLXN), Inovio Pharmaceuticals (INO), T2 Biosystems (TTOO), Arbutus Biopharma (ABUS) and BioCryst Pharmaceuticals (BCRX). What is Aravive's stock symbol? Aravive trades on the NASDAQ under the ticker symbol "ARAV." Who are Aravive's major shareholders? Aravive's stock is owned by many different retail and institutional investors. Top institutional shareholders include Affinity Asset Advisors LLC (0.00%), BlackRock Inc. (0.54%), Geode Capital Management LLC (0.51%), Renaissance Technologies LLC (0.36%) and Assenagon Asset Management S.A. (0.03%). Insiders that own company stock include Amato Giaccia, Gail Frances Mcintyre and Vinay Shah. View institutional ownership trends. How do I buy shares of Aravive? Shares of ARAV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Aravive's stock price today? One share of ARAV stock can currently be purchased for approximately $0.13. How much money does Aravive make? Aravive (NASDAQ:ARAV) has a market capitalization of $9.65 million and generates $9.14 million in revenue each year. The company earns $-76,320,000.00 in net income (profit) each year or ($1.75) on an earnings per share basis. How can I contact Aravive? Aravive's mailing address is River Oaks Tower 3730 Kirby Drive Suite 1200, Houston TX, 77098. The official website for the company is www.aravive.com. The company can be reached via phone at (936) 355-1910 or via email at christina@sternir.com. This page (NASDAQ:ARAV) was last updated on 9/28/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aravive, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.